Trial Profile
Open-label, individual dose titration study to evaluate safety, tolerability and pharmacokinetics of riociguat in children from 6 to less than 18 years of age with pulmonary arterial hypertension (PAH)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Riociguat (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Registrational
- Acronyms PATENT-CHILD
- Sponsors Bayer HealthCare; Bayer Yakuhin
- 29 Aug 2023 This trial has been completed in Poland according to European Clinical Trials Database record.
- 30 May 2022 Planned End Date changed from 25 Nov 2031 to 27 Jan 2031.
- 01 Apr 2022 This trial has been completed in Hungary according to European Clinical Trials Database record.